Improved Survival in Subset of Advanced Pancreatic Cancer

Adding nimotuzumab to gemcitabine significantly improved survival outcomes in a subset of patients with KRAS wild-type advanced pancreatic cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/975056?src=rss